Isotretinoin

Isotretinoin is prescribed to treat:

• Severe nodular acne • Various related conditions in the dermatology category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Isotretinoin (Accutane, Absorica, Claravis) is an oral retinoid used for severe nodular acne and for acne that has failed other treatment. It is the only acne treatment capable of producing durable remission rather than suppression, and it is also the most heavily regulated drug in dermatology because of its teratogenicity.

Mechanism of Action

Isotretinoin is 13-cis-retinoic acid, a vitamin A derivative. It is the only acne treatment that addresses all four elements of acne pathogenesis simultaneously.

It dramatically reduces sebaceous gland size and sebum production — the effect that matters most, since sebum is the substrate for everything downstream. It normalises follicular keratinisation, preventing the microcomedone formation that begins every lesion. It reduces Cutibacterium acnes colonisation indirectly by removing the lipid-rich environment the organism requires, without being an antibiotic. And it has direct anti-inflammatory effects.

Because sebaceous gland suppression persists after treatment ends, isotretinoin can produce lasting remission — roughly half of patients need no further treatment after a single adequate course. No other acne therapy does this; antibiotics, topical retinoids, and hormonal treatments all suppress disease while they are being taken.

Total cumulative dose matters more than daily dose for durability of response. Courses are dosed to a cumulative target, and stopping early because the skin has cleared is a well-recognised cause of relapse.

Pregnancy Prevention

Isotretinoin is a potent human teratogen. Exposure during pregnancy causes a characteristic pattern of severe craniofacial, cardiac, thymic, and central nervous system malformations, with very high rates of malformation and pregnancy loss among exposed pregnancies.

Because of this, prescribing in the United States operates under a mandatory risk management programme requiring registration of prescriber, pharmacy, and patient, two forms of contraception or documented abstinence, monthly pregnancy testing, and defined prescribing windows.

The programme is burdensome and it exists for a reason. The teratogenic risk is not probabilistic in the way most drug risks are — exposure during the critical period causes malformation at very high rates, and there is no safe dose.

The drug clears from the body within about a month, so pregnancy is avoided from a month before treatment until a month after it ends. This should be discussed frankly and without euphemism, including with adolescent patients, whose sexual activity should be asked about directly rather than assumed. Our dermatologic team manages these courses, and the FDA iPLEDGE programme sets out the requirements.

Clinical Use

Isotretinoin is indicated for severe nodulocystic acne, and also for moderate acne that has failed conventional therapy, that is scarring, or that is causing significant psychological distress — scarring in particular justifies earlier intervention, since it is permanent and preventable.

An initial flare in the first weeks is common and can be severe. Starting at a lower dose and escalating, and occasionally covering with a short course of oral corticosteroid in severe nodular disease, reduces this.

Mucocutaneous effects are universal and dose-related: dry lips in essentially every patient, dry eyes, dry nasal mucosa with nosebleeds, and dry skin. These are manageable with emollients and lip balm, and they resolve after treatment. Patients should be warned that contact lenses may become uncomfortable.

Sun sensitivity increases, which matters in this climate. Waxing and dermabrasion are avoided during and for six months after treatment because of impaired skin healing.

Doxycycline and other tetracyclines must not be combined with isotretinoin — the combination raises the risk of intracranial hypertension. Patients moving from an antibiotic to isotretinoin need the antibiotic stopped first.

Monitoring and Follow-Up

Monthly review during a course covers pregnancy testing where applicable, laboratory monitoring, and clinical response.

Lipids and liver enzymes are checked at baseline and periodically. Triglyceride elevation is the most common abnormality and is usually modest, though marked elevation raises pancreatitis risk and warrants dose reduction. Transaminase rises are usually mild and transient.

The relationship between isotretinoin and depression has been examined extensively and remains genuinely unsettled — severe acne itself carries substantial psychological morbidity, and treating it generally improves mood. The reasonable position is neither to dismiss the concern nor to withhold effective treatment, but to ask about mood at every visit, involve family where appropriate, and act on any deterioration. The MedlinePlus isotretinoin entry covers prescribing detail.

Inflammatory bowel disease has been raised as a possible association and is not supported by the weight of current evidence, though new bowel symptoms warrant assessment.

Relapse after a completed course is worth setting expectations about. Roughly half of patients need no further treatment; the rest have some recurrence, usually milder and often manageable with topical therapy rather than a second course. Relapse is more likely in younger patients, in those with truncal involvement, and where the cumulative dose target was not reached.

Special Populations

In women of childbearing potential the pregnancy prevention requirements are absolute, and this shapes the entire course.

In adolescents, isotretinoin is widely used and effective; growth plate effects are a theoretical concern that has not proved clinically significant. Bone and joint aches are common and usually mild.

In patients with hypertriglyceridemia, diabetes, obesity, or significant alcohol intake, lipid monitoring is more important. It is contraindicated in pregnancy, breastfeeding, and hypervitaminosis A, and vitamin A supplements should be stopped. Concurrent tetracyclines are contraindicated.

When to Contact Your Doctor

Seek urgent care for severe headache with visual changes, nausea, or vomiting, which may indicate raised intracranial pressure — particularly if you are also taking a tetracycline.

Report severe abdominal pain, which may indicate pancreatitis from raised triglycerides. Report any change in mood, depression, or thoughts of self-harm promptly, and tell someone close to you to watch for it.

Report new bowel symptoms — persistent diarrhoea, rectal bleeding, severe abdominal pain. Report yellowing of the skin or eyes. Report a severe acne flare in the early weeks rather than stopping treatment.

If you are or might be pregnant, stop the drug and contact us immediately. Do not donate blood during treatment or for a month afterwards.

To discuss whether isotretinoin is appropriate, manage side effects, or plan a course, contact us or schedule a visit.